Merck, Pfizer end patent feud over pneumococcal vaccines with royalty-centered settlement
A long-running patent battle between two pharma giants over their competing pneumococcal conjugate vaccines has come to an end.
Merck and Pfizer have reached a settlement agreement to dismiss patent claims for all their PCV products, Merck announced Thursday. It’s a deal that comes just a few months after both companies netted approvals for new vaccines, with Pfizer getting the rubber stamp for its 20-valent shot in June and Merck winning the green light for a 15-valent vaccine in July.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.